

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.*



## **Sinco Pharmaceuticals Holdings Limited**

**兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

### **EXTENSION OF COMPLETION DATE OF PLACING OF NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) dated 7 December 2021 (the “**Announcement**”) in relation to the placing of new shares under general mandate. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

#### **EXTENSION OF COMPLETION DATE**

As additional time is required for completion of administration procedures on the proposed Placing, the Company and the Placing Agent, after arm’s length negotiation, have entered into a supplemental agreement to the Placing Agreement on 30 December 2021 (after trading hours) to extend the Completion Date from no later than 30 December 2021 to no later than 3 January 2022.

Save and except the aforesaid extension of Completion Date, all the terms and conditions of the Placing Agreement remain unchanged and continue in full force and effect.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Hong Kong, 30 December 2021

*As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*